Erratum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D, Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment" Kidney Int. 2020;97:1287-1296.
Publication
, Journal Article
Rondeau, E; Scully, M; Ariceta, G; Barbour, T; Cataland, S; Heyne, N; Miyakawa, Y; Ortiz, S; Swenson, E; Vallee, M; Yoon, S-S; Kavanagh, D ...
Published in: Kidney Int
December 2020
Duke Scholars
Published In
Kidney Int
DOI
EISSN
1523-1755
Publication Date
December 2020
Volume
98
Issue
6
Start / End Page
1621
Location
United States
Related Subject Headings
- Urology & Nephrology
- 3202 Clinical sciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Rondeau, E., Scully, M., Ariceta, G., Barbour, T., Cataland, S., Heyne, N., … 311 Study Group. (2020). Erratum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D, Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment" Kidney Int. 2020;97:1287-1296. Kidney Int, 98(6), 1621. https://doi.org/10.1016/j.kint.2020.11.001
Rondeau, Eric, Marie Scully, Gema Ariceta, Tom Barbour, Spero Cataland, Nils Heyne, Yoshitaka Miyakawa, et al. “Erratum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D, Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment" Kidney Int. 2020;97:1287-1296.” Kidney Int 98, no. 6 (December 2020): 1621. https://doi.org/10.1016/j.kint.2020.11.001.
Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, et al. Erratum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D, Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment" Kidney Int. 2020;97:1287-1296. Kidney Int. 2020 Dec;98(6):1621.
Rondeau, Eric, et al. “Erratum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D, Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment" Kidney Int. 2020;97:1287-1296.” Kidney Int, vol. 98, no. 6, Dec. 2020, p. 1621. Pubmed, doi:10.1016/j.kint.2020.11.001.
Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D, Haller H, 311 Study Group. Erratum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D, Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment" Kidney Int. 2020;97:1287-1296. Kidney Int. 2020 Dec;98(6):1621.
Published In
Kidney Int
DOI
EISSN
1523-1755
Publication Date
December 2020
Volume
98
Issue
6
Start / End Page
1621
Location
United States
Related Subject Headings
- Urology & Nephrology
- 3202 Clinical sciences
- 1103 Clinical Sciences